SCHEMBL24150540

SCHEMBL24150540

C=CC(=O)Nc1cccc(-c2ccc3nccnc3c2)c1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ JAK3 P52333 3/20 0.60
▸ BTK Q06187 5/20 0.53
▸ ITK Q08881 3/20 0.52
▸ PLCG1 P19174 4/20 0.52
▸ TGM2 P21980 1/20 0.51
▸ MAP2K7 O14733 1/20 0.51
▸ AURKA O14965 1/20 0.51
▸ EGFR P00533 2/20 0.51
▸ JAK1 P23458 1/20 0.51
▸ TDP2 O95551 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ FYN P06241 1/20 0.50
▸ SRC P12931 1/20 0.50
▸ VCP P55072 1/20 0.50
▸ TGFBR1 P36897 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30190551 1.00 JAK3 (0.60) JAK3BTKITKPLCG1TGM2
SCHEMBL30190510 0.86 JAK3 (0.57) JAK3BTKITKPLCG1MAP2K7
SCHEMBL24150617 0.86 JAK3 (0.57) JAK3BTKITKPLCG1MAP2K7
SCHEMBL24150178 0.84 PLCG1 (0.57) JAK3BTKITKPLCG1MAP2K7
SCHEMBL30190644 0.84 PLCG1 (0.57) JAK3BTKITKPLCG1MAP2K7
SCHEMBL24150478 0.83 BTK (0.60) JAK3BTKITKPLCG1EGFR
SCHEMBL24150187 0.83 PLCG1 (0.56) JAK3BTKITKPLCG1EGFR
SCHEMBL24151412 0.83 BTK (0.57) JAK3BTKITKPLCG1MAP2K7
SCHEMBL24150139 0.83 GAK (0.52) JAK3BTKITKPLCG1MAP2K7
SCHEMBL24150554 0.83 JAK3 (0.63) JAK3BTKITKPLCG1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11926632-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2024-03-12 — — US disclosed
US-20230046427-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-02-16 — — US disclosed
US-20230046427-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-02-16 — — US disclosed
WO-2021262596-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2021-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230046427-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS JAK3 4427/4885BTK 4194/4885ITK 4359/4885
US-11926632-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS JAK3 4427/4885BTK 4194/4885ITK 4359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback